SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] UPLOAD:
[]
DQ [DAQO NEW ENERGY] F-1/A: (Original Filing)
[CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered (1)(2) Proposed maximum Amount of Ordinary Shares, par value $0.0001 per share (3) $100,000,000 $7,130.00 (4) (1) Estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(o) under the Securities Act of 1933. (2) (3) American depositary shares issuable upon] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in this Amendment No. 5 to Registration Statement No. 333-164307 of our report dated August 18, 2010 relating to the consolidated financial statements and financial statement schedule of Daqo New Energy Corp., which report expresses an unqualified opinion on the consolidated financial statements and financial statement schedule and]
DQ [DAQO NEW ENERGY] F-1/A: CALCULATION OF REGISTRATION FEE Title of each class
[CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered (1)(2) Proposed maximum Amount of Ordinary Shares, par value $0.0001 per share (3) $100,000,000 $7,130.00 (4) (1) Estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(o) under the Securities Act of 1933. (2) (3) American depositary shares issuable upon] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in this Amendment No. 5 to Registration Statement No. 333-164307 of our report dated August 18, 2010 relating to the consolidated financial statements and financial statement schedule of Daqo New Energy Corp., which report expresses an unqualified opinion on the consolidated financial statements and financial statement schedule and]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[EX-99.1 2 ex99-1.htm] [EX-99.2 3 ex99-2.htm]
BSPM [Biostar Pharmaceuticals,] 8-K: EX-99.1 2 ex99-1.htm
[EX-99.1 2 ex99-1.htm] [EX-99.2 3 ex99-2.htm]
CNET [ChinaNet Online] 8-A12B: (Original Filing)
[Item 1. Item 2.]
CO [Chinard Bloodrp] SC TO-C: SCHEDULE TO (Rule 14d-100) Tender Offer Statement under
[SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section14(d)(1) or 13(e)(1) CHINARD BLOODRPORATION (Name of Subjectmpany (Issuer) and Name of Filing Person (Issuer)) (Title of Class of Securities)G211071181 )bert Chen +852 3605 8180bert.chen@chinacordbloodcorp.com 48th Floor, Bank of China Tower 1 Garden Road Central, Hong KongR.] [HONG KONG, China, September 13, 2010 - Chinard Bloodrporation Ms. Ting Zheng, Chairperson and CEO of Chinard Bloodrporationmmented, The proposed exchange offer will streamline and simplify our shareholding structure wellrporate structure.out Chinard Bloodrporation http://www.chinacordbloodcorp.com Chinard Bloodrporation is the first and largestrd blood banking operator in China in terms of geographicalverage and is the onlyrd blood]
